Fusion Antibodies (LON:FAB) Trading Down 2% – Should You Sell?

Fusion Antibodies plc (LON:FAB)’s share price fell 2% on Tuesday . The company traded as low as GBX 9.80 ($0.12) and last traded at GBX 10 ($0.13). 3,455,756 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 4,450,999 shares. The stock had previously closed at GBX 10.20 ($0.13).

Fusion Antibodies Stock Down 10.0 %

The firm’s 50 day simple moving average is GBX 5.61 and its 200-day simple moving average is GBX 4.25. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40. The stock has a market capitalization of £8.75 million, a price-to-earnings ratio of -229.43 and a beta of 0.49.

Insider Activity at Fusion Antibodies

In other news, insider Adrian Kinkaid bought 83,728 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was acquired at an average cost of GBX 4 ($0.05) per share, with a total value of £3,349.12 ($4,190.07). 11.39% of the stock is owned by company insiders.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.